Navigation Links
Case Zeltiq - CLINIPRO: The Court Upholds Clinipro - LipoCryo Claim
Date:1/29/2013

BARCELONA, Spain, January 29, 2013 /PRNewswire/ --

CLINIPRO, a Spanish company that manufactures medical-aesthetical devices, announces that the Barcelona Trade Court No. 5 has dictated a resolution, dated January 25th, 2013, fully disregarding the lawsuit promoted by Zeltiq Aesthetics Inc. (Nasdaq: ZLTQ) and Massachusetts General Hospital (MGH) against CLINIPRO, for alleged infringements of patents and disloyal competence acts. The matter has been carried out by the SOL MUNTAÑOLA & ASOCIADOS office, which CLINIPRO put in charge of the legal management.

The sentence states that the patents of the plaintiffs are annulated, due to the lack of inventive activity (the procedure patent) and to the lack of new items (the device patent), so that the presented claim is refused. Moreover, the sentence denies the disloyal acts existence, also a part of the claim, among other reasons, because Zeltiq and MGH cannot appropriate themselves of the name that describes the cold-application technique used to reduce fat (cryolipolysis). The sentence imposes on Zeltiq and MGH the payment of the costs incurred, although CLINIPRO is considering the possibility of requesting, also, the damages and prejudices caused.

We must recall that, due to the claim presented by MGH and Zeltiq against CLINIPRO for copyrights violation, a preliminary order was dictated on May 5th, 2012, where cautionary measures were taken against marketing LipoCryo in Spain. Later, those measures were declared without effect by means of a sentence dated June 25th, 2012, the court accepting the deposit of a substitutive caution. Now, by this new sentence, the caution measures have been immediately cancelled.

SOL MUNTAÑOLA ABOGADOS, in charge of defending CLINIPRO in this matter, expressed their satisfaction: "The sentence is clear and to the point, so that there is no doubt about the lawfulness of Lipocryo," has said Mario Sol , the firm's founding partner and one of the lawyers that was in charge of this case.

About CLINIPRO

Clinipro is a company with presence in over 40 countries and its vision is to remain being the benchmark and the effective, secure and non-invasive alternative to surgical treatments of aesthetic medicine. Always aimed at offering the latest technology and staying ahead of market trends to provide the most innovative technologies. Clinipro, with 20 years of industry experience, has professional technicians and highly qualified physicians that support their brands results such as LipoCryo and Mesostar, among others, which contribute to people's physical well being through safe and effective procedures.

More information
Fermín San Martín
fsanmartin@clinipro.net
+34-935-903-108


'/>"/>
SOURCE Clinipro S.L
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
2. Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
3. California Healthcare Institute Issues Statement on Supreme Court Ruling on the Affordable Care Act
4. Medzilla.com Special Report: Unemployed Can Breathe a Little Freer After Supreme Court's Affordable Care Act Ruling
5. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
6. K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
7. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
8. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
9. Three Blockbuster Patent Cases at the Supreme Court This Term
10. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
11. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):